-
TCR2 Therapeutics (TCRR) Prices 4.59M Share Common Offering at $30.50/Sh
-
TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock
-
TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock
-
TCR2 Therapeutics (TCRR) Announces $125M Proposed Public Offering of Common Stock
-
TCR² Therapeutics Announces Proposed Public Offering of Common Stock
-
TCR² Therapeutics Announces Proposed Public Offering of Common Stock
-
TCR2 Therapeutics (TCRR) Prices 8M Share Common Offering at $15.50/Sh
-
TCR² Therapeutics Announces Pricing of Public Offering of Common Stock
-
TCR² Therapeutics Announces Pricing of Public Offering of Common Stock
-
TCR2 Therapeutics (TCRR) to Offer 6M Common Shares
-
TCR² Therapeutics Announces Proposed Public Offering of Common Stock
-
TCR² Therapeutics Announces Proposed Public Offering of Common Stock
-
TCR2 Therapeutics (TCRR) PT Raised to $45 at BMO Capital
-
TCR2 Therapeutics (TCRR) PT Lowered to $35 at BMO Capital
-
BMO Capital Starts TCR2 Therapeutics (TCRR) at Outperform
-
TCR2 Therapeutics Announces Exercise of Over-Allotment Option
-
TCR2 Therapeutics (TCRR) IPO Opens Flat
-
TCR2 Therapeutics Inc. (TCRR) Prices 5M Share IPO at $15/Sh
-
TCR2 Therapeutics Announces Pricing of Initial Public Offering of Common Stock
-
TCR2 Therapeutics Inc. (TCRR) Announces Proposed 5M Share IPO Between $14-$16/Sh
-
TCR2 Therapeutics Launches Proposed Initial Public Offering

